NLRX1 suppresses tumorigenesis and attenuates histiocytic sarcoma through the negative regulation of NF-ΛB signaling

Oncotarget

Volumn 7, Issue 22, 2016, Pages 33096-33110

  Coutermarsh Ott, Sheryl ^a   Simmons, Alysha ^a   Capria, Vittoria ^a   LeRoith, Tanya ^a   Wilson, Justin E ^b   Heid, Bettina ^a   Philipson, Casandra W ^c   Qin, Qizhi ^a   Hontecillas Magarzo, Raquel ^c   Bassaganya Riera, Josep ^c   Ting, Jenny P Y ^b   Dervisis, Nikolaos ^a   Allen, Irving C ^a  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

Author keywords

Cancer; Inflammation; NLR; Nod like receptor; Urethane

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NLRX1 PROTEIN; PROTEIN KINASE B; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; MITOCHONDRIAL PROTEIN; NLRX1 PROTEIN, HUMAN; NLRX1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CARCINOGENESIS; CELL DEATH; CONTROLLED STUDY; FEMALE; GENE CONTROL; HISTIOCYTIC SARCOMA; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SPLEEN CANCER; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

ANIMALS; CARCINOGENESIS; DISEASE MODELS, ANIMAL; FEMALE; HISTIOCYTIC SARCOMA; HUMANS; MICE; MICE, INBRED C57BL; MITOCHONDRIAL PROTEINS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84973534439     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8861     Document Type: Article

References (33)

1. Laviv Y, Zagzag D, Fichman-Horn S, Michowitz S. Primary central nervous system histiocytic sarcoma. Brain tumor pathology. 2013; 30:192-195.
2. Lee D, Kim YB, Chung SH, Lee SR, Byun CS, Han SU, Han JH. Primary gastric histiocytic sarcoma reminiscent of inflammatory pseudotumor: a case report with review of the literature. Korean journal of pathology. 2014; 48:258-262.
3. Chatterjee S, Crozet L, Damotte D, Iribarren K, Schramm C, Alifano M, Lupo A, Cherfils-Vicini J, Goc J, Katsahian S, Younes M, Dieu-Nosjean MC, Fridman WH, Sautes-Fridman C, Cremer I. TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. Cancer research. 2014; 74:5008-5018.
4. Samara KD, Antoniou KM, Karagiannis K, Margaritopoulos G, Lasithiotaki I, Koutala E, Siafakas NM. Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis. International journal of oncology. 2012; 40:1397-1404.
5. Xu L, Wen Z, Zhou Y, Liu Z, Li Q, Fei G, Luo J, Ren T. MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway. Molecular biology of the cell. 2013; 24:42-55.
6. Bhatelia K, Singh K, Singh R. TLRs: linking inflammation and breast cancer. Cellular signalling. 2014; 26:2350-2357.
7. Sipos F, Furi I, Constantinovits M, Tulassay Z, Muzes G. Contribution of TLR signaling to the pathogenesis of colitis-associated cancer in inflammatory bowel disease. World journal of gastroenterology: WJG. 2014; 20:12713-12721.
8. Allen IC. Non-Inflammasome Forming NLRs in Inflammation and Tumorigenesis. Frontiers in immunology. 2014; 5:169.
9. Davis BK, Philipson C, Hontecillas R, Eden K, Bassaganya-Riera J, Allen IC. Emerging significance of NLRs in inflammatory bowel disease. Inflammatory bowel diseases. 2014; 20:2412-2432.
10. Bryant CE, Monie TP. Mice, men and the relatives: cross-species studies underpin innate immunity. Open biology. 2012; 2:120015.
11. Arnoult D, Soares F, Tattoli I, Castanier C, Philpott DJ, Girardin SE. An N-terminal addressing sequence targets NLRX1 to the mitochondrial matrix. Journal of cell science. 2009; 122:3161-3168.
12. Lei Y, Wen H, Ting JP. The NLR protein, NLRX1, and its partner, TUFM, reduce type I interferon, and enhance autophagy. Autophagy. 2013; 9:432-433.
13. Lei Y, Wen H, Yu Y, Taxman DJ, Zhang L, Widman DG, Swanson KV, Wen KW, Damania B, Moore CB, Giguere PM, Siderovski DP, Hiscott J, Razani B, Semenkovich CF, Chen X, et al. The mitochondrial proteins NLRX1 and TUFM form a complex that regulates type I interferon and autophagy. Immunity. 2012; 36:933-946.
14. Allen IC, Moore CB, Schneider M, Lei Y, Davis BK, Scull MA, Gris D, Roney KE, Zimmermann AG, Bowzard JB, Ranjan P, Monroe KM, Pickles RJ, Sambhara S, Ting JP. NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-kappaB signaling pathways. Immunity. 2011; 34:854-865.
15. Moore CB, Bergstralh DT, Duncan JA, Lei Y, Morrison TE, Zimmermann AG, Accavitti-Loper MA, Madden VJ, Sun L, Ye Z, Lich JD, Heise MT, Chen Z, Ting JP. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature. 2008; 451:573-577.
16. Singh K, Poteryakhina A, Zheltukhin A, Bhatelia K, Prajapati P, Sripada L, Tomar D, Singh R, Singh AK, Chumakov PM, Singh R. NLRX1 acts as tumor suppressor by regulating TNF-alpha induced apoptosis and metabolism in cancer cells. Biochimica et biophysica acta. 2015; 1853:1073-1086.
17. Soares F, Tattoli I, Rahman MA, Robertson SJ, Belcheva A, Liu D, Streutker C, Winer S, Winer DA, Martin A, Philpott DJ, Arnoult D, Girardin SE. The mitochondrial protein NLRX1 controls the balance between extrinsic and intrinsic apoptosis. The Journal of biological chemistry. 2014; 289:19317-19330.
18. Davis BK. Isolation, culture, and functional evaluation of bone marrow-derived macrophages. Methods in molecular biology (Clifton, NJ). 2013; 1031:27-35.
19. Bauer AK, Cho HY, Miller-Degraff L, Walker C, Helms K, Fostel J, Yamamoto M, Kleeberger SR. Targeted deletion of Nrf2 reduces urethane-induced lung tumor development in mice. PloS one. 2011; 6:e26590.
20. Horio Y, Chen A, Rice P, Roth JA, Malkinson AM, Schrump DS. Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Molecular carcinogenesis. 1996; 17:217-223.
21. Shimkin MB, Polissar MJ. Some quantitative observations on the induction and growth of primary pulmonary tumors in strain A mice receiving urethan. J Natl Cancer Inst. 1955; 16:75-97.
22. Xia X, Cui J, Wang HY, Zhu L, Matsueda S, Wang Q, Yang X, Hong J, Songyang Z, Chen ZJ, Wang RF. NLRX1 negatively regulates TLR-induced NF-kappaB signaling by targeting TRAF6 and IKK. Immunity. 2011; 34:843-853.
23. Nikolic Nielsen L, Kjelgaard-Hansen M, Kristensen AT. Monocyte chemotactic protein-1 and other inflammatory parameters in Bernese Mountain dogs with disseminated histiocytic sarcoma. Veterinary journal (London, England: 1997). 2013; 198:424-428.
24. Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV, Connelly L, Yull FE, Fingleton B, Blackwell TS. Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:18514-18519.
25. Koblansky AA, Truax AD, Liu R, Montgomery SA, Ding S, Wilson JE, Brickey WJ, Muhlbauer M, McFadden RT, Hu P, Li Z, Jobin C, Lund PK, Ting JP. The Innate Immune Receptor NLRX1 Functions as a Tumor Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting Signals. Cell reports. 2016; 14:2562-2575.
26. Tattoli I, Killackey SA, Foerster EG, Molinaro R, Maisonneuve C, Rahman MA, Winer S, Winer DA, Streutker CJ, Philpott DJ, Girardin SE. NLRX1 Acts as an Epithelial-Intrinsic Tumor Suppressor through the Modulation of TNF-Mediated Proliferation. Cell reports. 2016; 14:2576-2586.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
28. Yang J, Kantrow S, Sai J, Hawkins OE, Boothby M, Ayers GD, Young ED, Demicco EG, Lazar AJ, Lev D, Richmond A. INK4a/ARF [corrected] inactivation with activation of the NF-kappaB/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma. Cancer research. 2012; 72:4682-4695.
29. Willems SM, Schrage YM, Bruijn IH, Szuhai K, Hogendoorn PC, Bovee JV. Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option. Molecular cancer. 2010; 9:257.
30. Wilson JE, Petrucelli AS, Chen L, Koblansky AA, Truax AD, Oyama Y, Rogers AB, Brickey WJ, Wang Y, Schneider M, Muhlbauer M, Chou WC, Barker BR, Jobin C, Allbritton NL, Ramsden DA, et al. Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt. Nature medicine. 2015; 21:906-913.
31. Carrasco DR, Fenton T, Sukhdeo K, Protopopova M, Enos M, You MJ, Di Vizio D, Nogueira C, Stommel J, Pinkus GS, Fletcher C, Hornick JL, Cavenee WK, Furnari FB, Depinho RA. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer cell. 2006; 9:379-390.
32. Soare T, Noble PJ, Hetzel U, Fonfara S, Kipar A. Paraneoplastic syndrome in haemophagocytic histiocytic sarcoma in a dog. Journal of comparative pathology. 2012; 146:168-174.
33. Kupershmidt I, Su QJ, Grewal A, Sundaresh S, Halperin I, Flynn J, Shekar M, Wang H, Park J, Cui W, Wall GD, Wisotzkey R, Alag S, Akhtari S, Ronaghi M. Ontology-based meta-analysis of global collections of high-throughput public data. PloS one. 2010; 5.